Mumbai : Mumbai Angels, a premium platform for early stage investments, has invested in Mestastop Solutions, a cancer metastasis drug discovery and predictive diagnostics-focused biotech, based out of Bengaluru. Mestastop Solutions has secured investment from Mumbai Angels for the second time via Mumbai Angels Network Angel Fund 1, since its initial backing in 2020*. The recent funding round participation was from multiple angel investors and Malpani Ventures.

Mestastop Solutions plans to leverage the funds to generate a PoC (proof of concept) around the novel target and position two approved drugs for clinical trials to explore the delaying of metastasis for primary tumour patients in an adjuvant setting.

Ms Nandini Mansinghka, CEO of Mumbai Angels said,” Mestastop is working on a noble cause to develop anti-metastatic drugs and it is an honour for us to be part of this journey. We believe that with the recent funding, Mestastop will be able to strengthen its research which can help in delaying metastasis and save countless lives. Our continued investment in the company indicates our confidence and belief in Mestastop Solutions’ potential to make a meaningful impact.”

Arnab Roy Chowdhury, Founder,  Mestastop Solutions said, “We, at Mestastop Solutions, are immensely grateful to Mumbai Angels and other investors for believing in our vision and backing our journey. With this investment, we intend to realise our dream of offering unique, tech-backed strategies to develop anti-metastatic drugs that focus on delaying metastasis causing the spread of cancer. We are happy that Mumbai Angels has once again trusted us in this round of investment. This continued support further solidifies the partnership between us.”

Mestastop is a deep-tech startup that focuses on the functional properties of patient primary tumour samples to identify distinct phenotypes that can act as markers of metastatic cells. Over the past five years, Mestastop has integrated wet lab biology and machine learning algorithms to develop three proprietary platforms to unravel metastasis biology.

The platforms thread all discovery modalities, connecting in vitro, in vivo, and ex-vivo patient translational data. 90% of cancer deaths are caused by metastasis. So far, no approved therapies or approaches targeting metastasis have been successful in clinical trials. Mestastop’s solutions address this critical gap. The company has filed for multiple patents in the USA and Europe and currently has two ongoing European collaborations and three Indian collaborations.